LUNG-CANCER RISK IN RELATION TO THE CYP2C9-ASTERISK-1 CYP2C9-ASTERISK-2 GENETIC-POLYMORPHISM AMONG AFRICAN-AMERICANS AND CAUCASIANS IN LOS-ANGELES-COUNTY, CALIFORNIA/
Sj. London et al., LUNG-CANCER RISK IN RELATION TO THE CYP2C9-ASTERISK-1 CYP2C9-ASTERISK-2 GENETIC-POLYMORPHISM AMONG AFRICAN-AMERICANS AND CAUCASIANS IN LOS-ANGELES-COUNTY, CALIFORNIA/, Pharmacogenetics, 6(6), 1996, pp. 527-533
CYP2C9 is involved in the metabolism of warfarin and a wide array of o
ther therapeutic agents. It also appears to play a role, along with ot
her cytochrome P450 enzymes, in the metabolism of benzo[a]pyrene, a ca
rcinogen in tobacco smoke, A relatively common allelic variant (termed
R144C, Cys(144) Or more recently CYP2C92) has been described that re
sults in the substitution of cysteine for arginine at residue 144 and
appears to reduce enzyme activity. We therefore examined the possible
association between the presence of the CYP2C92 variant allele and ri
sk of lung cancer using peripheral blood DNA from 329 incident cases o
f lung cancer (152 African-American and 177 Caucasian) and 700 (239 Af
rican-American and 461 Caucasian) population controls in Los Angeles C
ounty, California, Among the population controls the frequency of the
CYP2C92 variant allele was lower (p = 0.00002) among African-American
s (0.036) than among Caucasians (0.100). The presence of the CYP2C92
variant allele was not associated with a decreased risk of lung cancer
; slight but nonstatistically significant elevations in risk were obse
rved for both African-Americans [odds ratio (OR) 1.22, 95% confidence
interval (CI) 0.48-3.11] and Caucasians (OR = 1.55, 95% CI 0.96-2.48),
The ORs were slightly and nonsignificantly elevated for all histologi
c types without substantive variation. The association also did not va
ry materially according to smoking history or whether subjects had the
homozygous deletion of the GSTM1 gene, We found no support for the hy
pothesis that the CYP2C92 variant allele decreases the risk of lung c
ancer, The role of P450s, including CYP2C9, in benzo[a]pyrene metaboli
sm is not fully defined, and CYP2C9 catalyses detoxication as well as
activation steps, Thus it is not inconceivable that diminished CYP2C9
activity could increase metabolic activation of benzo[cr]pyrene to car
cinogenic intermediates. Nonetheless, the small increased risk associa
ted the CYP2C92 variant allcle in our data is consistent with chance
and should not be overinterpreted.